Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects

American Heart Journal

Volumn 164, Issue 5, 2012, Pages 672-680

  Rosenson, Robert S ^a   Wright, R Scott ^b   Farkouh, Michael ^a,c   Plutzky, Jorge ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALEGLITAZAR; FENOFIBRATE; GEMFIBROZIL; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TELMISARTAN; TESAGLITAZAR; TROGLITAZONE;

ADIPOGENESIS; ANTIDIABETIC ACTIVITY; ARTICLE; BLADDER CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DNA BINDING; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATTY ACID OXIDATION; FRACTURE; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; LIGAND BINDING; LIPID METABOLISM; LIVER TOXICITY; MONOTHERAPY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUMOYLATION;

EID: 84868607245     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.06.023     Document Type: Review

References (78)

1. H. Kramer, G. Cao, and L. Dugas Increasing BMI and waist circumference and prevalence of obesity among adults with type 2 diabetes: the National Health and Nutrition Examination Surveys J Diabetes Complications 24 2010 368 374
2. L.L. Lipscombe, and J.E. Hux Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study Lancet 369 2007 750 756
3. R.S. Rosenson, P. Fioretto, and P.M. Dodson Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 218 2011 13 18
4. E. Brun, R.G. Nelson, and P.H. Bennett Diabetes duration and cause-specific mortality in the Verona Diabetes Study Diabetes Care 23 2000 1119 1123
5. C.S. Fox, L. Sullivan, and R.B. D'Agostino Sr. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study Diabetes Care 27 2004 704 708
6. S.G. Wannamethee, A.G. Shaper, and P.H. Whincup Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors Arch Intern Med 171 2011 404 410
7. J.C. Fruchart, F.M. Sacks, and M.P. Hermans The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient Diab Vasc Dis Res 5 2008 319 335
8. P. Fioretto, P.M. Dodson, and D. Ziegler Residual microvascular risk in diabetes: unmet needs and future directions Nat Rev Endocrinol 6 2010 19 25
9. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
10. K. Pyorala, T.R. Pedersen, and J. Kjekshus Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 20 1997 614 620
11. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
12. R. Collins, J. Armitage, and S. Parish MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
13. H.N. Ginsberg, M.B. Elam, and L.C. Lovato Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
14. M. Jun, C. Foote, and J. Lv Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
15. P.M. Kearney, L. Blackwell, and R. Collins Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
16. A. Keech, R.J. Simes, and P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
17. K.K. Ray, S.R. Seshasai, and S. Wijesuriya Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 2009 1765 1772
18. Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009;151(1):1-10, W11-12.
19. P. Gaede, H. Lund-Andersen, and H.H. Parving Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 2008 580 591
20. G.C. Alexander, N.L. Sehgal, and R.M. Moloney National trends in treatment of type 2 diabetes mellitus, 1994-2007 Arch Intern Med 168 2008 2088 2094
21. J.W. Jukema, C.W. Chiang, and J. Ferrieres Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2 Curr Med Res Opin 26 2010 2589 2597
22. R.T. Yan, A.T. Yan, and M. Tan Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes Am Heart J 152 2006 676 683
23. Recommendations for healthcare system and self-management education interventions to reduce morbidity and mortality from diabetes Am J Prev Med 22 4 Suppl 2002 10 14
24. E.I. Hammouda Overcoming barriers to diabetes control in geriatrics Int J Clin Pract 65 2011 420 424
25. J.B. Saaddine, B. Cadwell, and E.W. Gregg Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002 Ann Intern Med 144 2006 465 474
26. J.D. Brown, and J. Plutzky Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets Circulation 115 2007 518 533
27. J. Plutzky The PPAR-RXR transcriptional complex in the vasculature: energy in the balance Circ Res 108 2011 1002 1016
28. C.K. Glass Potential roles of the peroxisome proliferator-activated receptor-gamma in macrophage biology and atherosclerosis J Endocrinol 169 2001 461 464
29. B. Staels, N. Vu-Dac, and V.A. Kosykh Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates J Clin Invest 95 1995 705 712
30. V. Clavey, S. Lestavel-Delattre, and C. Copin Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E Arterioscler Thromb Vasc Biol 15 1995 963 971
31. K. Schoonjans, B. Staels, and J. Auwerx The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation Biochim Biophys Acta 1302 1996 93 109
32. I.P. Torra, G. Chinetti, and C. Duval Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice Curr Opin Lipidol 12 2001 245 254
33. G. Chinetti-Gbaguidi, J.C. Fruchart, and B. Staels Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy Curr Opin Pharmacol 5 2005 177 183
34. P. Libby, and J. Plutzky Diabetic macrovascular disease: the glucose paradox? Circulation 106 2002 2760 2763
35. N. Marx, U. Schonbeck, and M.A. Lazar Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells Circ Res 83 1998 1097 1103
36. N. Marx, G. Sukhova, and C. Murphy Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro Am J Pathol 153 1998 17 23
37. Y. Iwamoto, K. Kosaka, and T. Kuzuya Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy Diabetes Care 19 1996 151 156
38. B.B. Kahn, and T.E. McGraw Rosiglitazone, PPARgamma, and type 2 diabetes N Engl J Med 363 2010 2667 2669
39. R.S. Rosenson Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus Am J Cardiol 99 2007 96B 104B
40. T. Mazzone, P.M. Meyer, and S.B. Feinstein Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2006 2572 2581
41. C.J. Rosen Revisiting the rosiglitazone story - lessons learned N Engl J Med 363 2010 803 806
42. J.A. Dormandy, B. Charbonnel, and D.J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
43. D.J. Betteridge, R.A. DeFronzo, and R.J. Chilton PROactive: time for a critical appraisal Eur Heart J 29 2008 969 983
44. P.B. Watkins Insight into hepatotoxicity: the troglitazone experience Hepatology 41 2005 229 230
45. P. Home Safety of PPAR agonists Diabetes Care 34 Suppl. 2 2011 S215 S219
46. D. Glintborg, M. Andersen, and C. Hagen Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial J Clin Endocrinol Metab 93 2008 1696 1701
47. C. Piccinni, D. Motola, and G. Marchesini Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting Diabetes Care 34 2011 1369 1371
48. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
49. D.J. Graham, R. Ouellet-Hellstrom, and T.E. MaCurdy Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone JAMA 304 2010 411 418
50. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim: European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/public-health-alerts/2010/09/human-pha-detail-000020. jsp&mid=&source=homeMedSearch&category=human. Published October 6, 2011.
51. US Food and Drug Administration. FDA Drug Safety Communication: Updated drug labels for rosiglitazone-containing medicines. http://www.fda.gov/Drugs/ DrugSafety/ucm266555.htm. Published August 4, 2011. Accessed September 27, 2011.
52. US Food and Drug Administration. FDA Drug Safety Communication: Updated drug labels for pioglitazone-containing medicines. http://www.fda.gov/Drugs/ DrugSafety/ucm266555.htm. Published August 4, 2011. Accessed September 27, 2011.
53. J.H. Choi, A.S. Banks, and J.L. Estall Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5 Nature 466 2010 451 456
54. M.E. Marketou, J.E. Kontaraki, and N.A. Tsakountakis Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension Am J Cardiol 107 2011 59 63
55. T. Matsumura, H. Kinoshita, and N. Ishii Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-gamma in macrophages Arterioscler Thromb Vasc Biol 31 2011 1268 1275
56. K. Toyama, T. Nakamura, and K. Kataoka Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-gamma-dependent activity Biochem Biophys Res Commun 410 2011 508 513
57. H.B. Rubins, S.J. Robins, and D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
58. M.H. Frick, O. Elo, and K. Haapa Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
59. R.S. Rosenson Field of confusion: future prospects for fibrate therapy in cardiovascular disease Curr Atheroscler Rep 8 2006 219 222
60. W.V. Brown Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection Am J Cardiol 102 2008 10L 13L
61. E.Y. Chew, W.T. Ambrosius, and M.D. Davis Effects of medical therapies on retinopathy progression in type 2 diabetes N Engl J Med 363 2010 233 244
62. A.C. Keech, P. Mitchell, and P.A. Summanen Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 370 2007 1687 1697
63. K. Rajamani, P.G. Colman, and L.P. Li Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial Lancet 373 2009 1780 1788
64. C. Fievet, J.C. Fruchart, and B. Staels PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome Curr Opin Pharmacol 6 2006 606 614
65. A. Benardeau, J. Benz, and A. Binggeli Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes Bioorg Med Chem Lett 19 2009 2468 2473
66. M.A. Cavender, and A.M. Lincoff Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus Am J Cardiovasc Drugs 10 2010 209 216
67. R.R. Henry, A.M. Lincoff, and S. Mudaliar Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study Lancet 374 2009 126 135
68. A.M. Lincoff, K. Wolski, and S.J. Nicholls Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 2007 1180 1188
69. S.E. Nissen, K. Wolski, and E.J. Topol Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus JAMA 294 2005 2581 2586
70. A. Rubenstrunk, R. Hanf, and D.W. Hum Safety issues and prospects for future generations of PPAR modulators Biochim Biophys Acta 1771 2007 1065 1081
71. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Published December, 2008.
72. J. El-Hage Peroxisome proliferator-activated receptor (PPAR) agonists: preclinical and clinical cardiac safety considerations. FDA endocrinologic and metabolic drugs http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ ucm119071.pdf Accessed March 25, 2011
73. Hoffmann-La Roche. A study with aleglitazar in patients qith a recent acute coronary syndrome and type 2 diabetes mellitus. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01042769?term=aleglitazar&rank=5. Accessed February 27, 2012.
74. L.M. Younk, L. Uhl, and S.N. Davis Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk Expert Opin Drug Metab Toxicol 7 2011 753 763
75. S.J. Nicholls, E.M. Tuzcu, and K. Wolski Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study J Am Coll Cardiol 57 2011 153 159
76. S.E. Nissen, S.J. Nicholls, and K. Wolski Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 2008 1561 1573
77. P. Meerarani, J.J. Badimon, and E. Zias Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications Curr Mol Med 6 2006 501 514
78. F. Lalloyer, and B. Staels Fibrates, glitazones, and peroxisome proliferator-activated receptors Arterioscler Thromb Vasc Biol 30 2010 894 899